Land: Verenigd Koninkrijk
Taal: Engels
Bron: MHRA (Medicines & Healthcare Products Regulatory Agency)
Ascorbic acid
Crescent Pharma Ltd
A11GA01
Ascorbic acid
500mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 09060301; GTIN: 5017123039133
Patient Information Lea f l e t A S C O R B I C A C I D 50 0 M G T AB L E T S This medicine will be called Ascorbic Acid T a b l e t s in this l ea f l e t . READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE. • Keep this leaflet. You may need to read it again. • This medicine is only for you. Do not give it to anyone else to take. It may harm them, even if their symptoms are the same as yours. • If you have any further questions, please ask your doctor or pharmacist. • If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. IN THIS L E A FL E T : 1. What Ascorbic Acid Tablets are and what they a r e used f o r 2. Before you take Ascorbic Acid T a b l e t s 3. How to take Ascorbic Acid T a b l e t s 4. Possible side e ff e c t s 5. How to store Ascorbic Acid T a b l e t s 6. Further i n f o rm a t io n 1. WHAT ASCORBIC ACID TABLETS ARE A ND WHAT THEY ARE USED F O R These tablets contain the active ingredient, a s c o r b i c acid. Ascorbic acid is the chemical name for V i t a m i n C. The tablets can be used to increase the amount o f Vitamin C in the d i e t . Vitamin C Tablets are used to treat Vitamin C deficiency including the prevention and treatment of scurvy. 2. BEFORE YOU TAKE ASCORBIC ACID TA B LE T S SOME PEOPLE MUST NOT TAKE THESE T A B L E T S. DO NOT TAKE THESE TABLETS IF : • You know you are allergic to ascorbic acid or to any of the other ingredients ( t h e s e are listed in Section 6 ) • You suffer from hyperoxaluria ( e x c e ss oxalic acid i n the ur i n e ) . YOU MUST BE ESPECIALLY CAREFUL IF : • You are pregnant or b r ea s t f ee d i n g . • You have an intolerance to some sugars. T h e s e tablets contain lactose and su c r o s e. If any of the conditions above apply to you, p l ea s e discuss your treatment with your doctor before t a ki n g this m e d i c i n e. TAKING OTHER M E DICINES Ascorbic Acid Tablets can affect some o t h e r medicines you may be taking. Lees het volledige document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Ascorbic Acid Tablets BP 500 mg 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 500.0 mg of ascorbic acid. For excipients, see 6.1. 3 PHARMACEUTICAL FORM Tablet. Ascorbic Acid Tablets BP 500 mg are presented as white to off-white normal convex tablets 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Prevention and treatment of scurvy. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Adults and children over 6 years: Prophylactic: 25 - 75 mg daily. Note: this unit dosage form is unsuitable for prophylactic use. Therapeutic: not less than 250 mg daily in divided doses. Children under 6 years: This unit dosage form is unsuitable for children under 6 years. Elderly: Dosage same as for adults. Route of administration Oral. 4.3 CONTRAINDICATIONS Hypersensitivity to ascorbic acid or to any of the excipients. Hyperoxaluria. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE Excessive use of chewable ascorbic acid tablets may cause breakdown of enamel and increased incidence of caries. Increased intake of ascorbic acid over a prolonged period may result in an increase in renal clearance of ascorbic acid and deficiency may result if it is withdrawn rapidly. Large doses are associated with the formation of renal calcium oxalate calculi. The administration of therapeutic doses of ascorbic acid may interfere with Clinistix test for glucosuria giving a false negative result. 4.5 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION Concurrent use of ascorbic acid with barbiturates or primidone may increase the urinary excretion of ascorbic acid. Concurrent use with cellulose sodium phosphate may result in metabolism of ascorbic acid to oxalate. Concurrent use of desferrioxamine with ascorbic acid enhances tissue iron toxicity especially in the heart. Concurrent administration of ascorbic acid with desferrioxamine enhances urinary iron excretion. Cases of cardiomyopathy and congestive heart failure have been reported in patients with idio Lees het volledige document